1
|
Koekkoek LL, Kool T, Eggels L, van der Gun LL, Lamuadni K, Slomp M, Diepenbroek C, Serlie MJ, Kalsbeek A, la Fleur SE. Activation of nucleus accumbens μ-opioid receptors enhances the response to a glycaemic challenge. J Neuroendocrinol 2021; 33:e13036. [PMID: 34528311 PMCID: PMC9286654 DOI: 10.1111/jne.13036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Revised: 08/10/2021] [Accepted: 08/20/2021] [Indexed: 11/30/2022]
Abstract
Opioids are known to affect blood glucose levels but their exact role in the physiological control of glucose metabolism remains unclear. Although there are numerous studies investigating the peripheral effects of opioid stimulation, little is known about how central opioids control blood glucose and which brain areas are involved. One brain area possibly involved is the nucleus accumbens because, as well as being a key site for opioid effects on food intake, it has also been implicated in the control of blood glucose levels. Within the nucleus accumbens, μ-opioid receptors are most abundantly expressed. Therefore, in the present study, we investigated the role of μ-opioid receptors in the nucleus accumbens in the control of glucose metabolism. We show that infusion of the μ-opioid receptor agonist [d-Ala2 , N-MePhe4 , Gly-ol]-enkephalin (DAMGO) in the nucleus accumbens by itself does not affect blood glucose levels, but it enhances the glycaemic response after both an insulin tolerance test, as well as a glucose tolerance test. These findings indicate that the nucleus accumbens plays a role in the central effects of opioids on glucose metabolism, and highlight the possibility of nucleus accumbens μ-opioid receptors as a therapeutic target for enhancing the counter-regulatory response.
Collapse
Affiliation(s)
- Laura L. Koekkoek
- Amsterdam University Medical Center, Location AMCLaboratory of EndocrinologyDepartment of Clinical ChemistryAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Amsterdam University Medical Center, Location AMCDepartment of Endocrinology and MetabolismAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Metabolism and Reward GroupAn Institute of the Royal Netherlands Academy of Arts and SciencesNetherlands Institute for NeuroscienceAmsterdamThe Netherlands
| | - Tess Kool
- Amsterdam University Medical Center, Location AMCLaboratory of EndocrinologyDepartment of Clinical ChemistryAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Amsterdam University Medical Center, Location AMCDepartment of Endocrinology and MetabolismAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Metabolism and Reward GroupAn Institute of the Royal Netherlands Academy of Arts and SciencesNetherlands Institute for NeuroscienceAmsterdamThe Netherlands
| | - Leslie Eggels
- Amsterdam University Medical Center, Location AMCLaboratory of EndocrinologyDepartment of Clinical ChemistryAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Amsterdam University Medical Center, Location AMCDepartment of Endocrinology and MetabolismAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Metabolism and Reward GroupAn Institute of the Royal Netherlands Academy of Arts and SciencesNetherlands Institute for NeuroscienceAmsterdamThe Netherlands
| | - Luna L. van der Gun
- Amsterdam University Medical Center, Location AMCLaboratory of EndocrinologyDepartment of Clinical ChemistryAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Amsterdam University Medical Center, Location AMCDepartment of Endocrinology and MetabolismAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Metabolism and Reward GroupAn Institute of the Royal Netherlands Academy of Arts and SciencesNetherlands Institute for NeuroscienceAmsterdamThe Netherlands
| | - Khalid Lamuadni
- Amsterdam University Medical Center, Location AMCLaboratory of EndocrinologyDepartment of Clinical ChemistryAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Amsterdam University Medical Center, Location AMCDepartment of Endocrinology and MetabolismAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Metabolism and Reward GroupAn Institute of the Royal Netherlands Academy of Arts and SciencesNetherlands Institute for NeuroscienceAmsterdamThe Netherlands
| | - Margo Slomp
- Amsterdam University Medical Center, Location AMCLaboratory of EndocrinologyDepartment of Clinical ChemistryAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Amsterdam University Medical Center, Location AMCDepartment of Endocrinology and MetabolismAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Metabolism and Reward GroupAn Institute of the Royal Netherlands Academy of Arts and SciencesNetherlands Institute for NeuroscienceAmsterdamThe Netherlands
| | - Charlene Diepenbroek
- Amsterdam University Medical Center, Location AMCLaboratory of EndocrinologyDepartment of Clinical ChemistryAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Amsterdam University Medical Center, Location AMCDepartment of Endocrinology and MetabolismAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Metabolism and Reward GroupAn Institute of the Royal Netherlands Academy of Arts and SciencesNetherlands Institute for NeuroscienceAmsterdamThe Netherlands
| | - Mireillle J. Serlie
- Amsterdam University Medical Center, Location AMCDepartment of Endocrinology and MetabolismAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
| | - Andries Kalsbeek
- Amsterdam University Medical Center, Location AMCLaboratory of EndocrinologyDepartment of Clinical ChemistryAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Amsterdam University Medical Center, Location AMCDepartment of Endocrinology and MetabolismAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Hypothalamic Integration MechanismsAn Institute of the Royal Netherlands Academy of Arts and SciencesNetherlands Institute for NeuroscienceAmsterdamThe Netherlands
| | - Susanne E. la Fleur
- Amsterdam University Medical Center, Location AMCLaboratory of EndocrinologyDepartment of Clinical ChemistryAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Amsterdam University Medical Center, Location AMCDepartment of Endocrinology and MetabolismAmsterdam NeuroscienceAmsterdam Gastroenterology, Endocrinology and MetabolismUniversity of AmsterdamAmsterdamThe Netherlands
- Metabolism and Reward GroupAn Institute of the Royal Netherlands Academy of Arts and SciencesNetherlands Institute for NeuroscienceAmsterdamThe Netherlands
| |
Collapse
|
2
|
Shang Y, Guo F, Li J, Fan R, Ma X, Wang Y, Feng N, Yin Y, Jia M, Zhang S, Zhou J, Wang H, Pei J. Activation of κ-Opioid Receptor Exerts the Glucose-Homeostatic Effect in Streptozotocin-Induced Diabetic Mice. J Cell Biochem 2014; 116:252-9. [DOI: 10.1002/jcb.24962] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2013] [Accepted: 08/29/2014] [Indexed: 12/15/2022]
Affiliation(s)
- Yulong Shang
- Department of Physiology; National Key Discipline of Cell Biology; Fourth Military Medical University; Xi'an 710032 Shaanxi Province China
| | - Fan Guo
- Department of Radiology; Xijing Hospital; Fourth Military Medical University; Xi'an 710033 Shaanxi Province China
| | - Juan Li
- Department of Physiology; National Key Discipline of Cell Biology; Fourth Military Medical University; Xi'an 710032 Shaanxi Province China
| | - Rong Fan
- Department of Physiology; National Key Discipline of Cell Biology; Fourth Military Medical University; Xi'an 710032 Shaanxi Province China
| | - Xinliang Ma
- Department of Physiology; National Key Discipline of Cell Biology; Fourth Military Medical University; Xi'an 710032 Shaanxi Province China
| | - Yuemin Wang
- Department of Physiology; National Key Discipline of Cell Biology; Fourth Military Medical University; Xi'an 710032 Shaanxi Province China
| | - Na Feng
- Department of Physiology; National Key Discipline of Cell Biology; Fourth Military Medical University; Xi'an 710032 Shaanxi Province China
| | - Yue Yin
- Department of Physiology; National Key Discipline of Cell Biology; Fourth Military Medical University; Xi'an 710032 Shaanxi Province China
| | - Min Jia
- Department of Physiology; National Key Discipline of Cell Biology; Fourth Military Medical University; Xi'an 710032 Shaanxi Province China
| | - Shumiao Zhang
- Department of Physiology; National Key Discipline of Cell Biology; Fourth Military Medical University; Xi'an 710032 Shaanxi Province China
| | - Jingjun Zhou
- Department of Physiology; National Key Discipline of Cell Biology; Fourth Military Medical University; Xi'an 710032 Shaanxi Province China
| | - Hongbing Wang
- Department of Cardiac Surgery; Xijing Hospital; Fourth Military Medical University; Xi'an 710033 Shaanxi Province China
| | - Jianming Pei
- Department of Physiology; National Key Discipline of Cell Biology; Fourth Military Medical University; Xi'an 710032 Shaanxi Province China
| |
Collapse
|
3
|
Czyzyk TA, Romero-Picó A, Pintar J, McKinzie JH, Tschöp MH, Statnick MA, Nogueiras R. Mice lacking δ-opioid receptors resist the development of diet-induced obesity. FASEB J 2012; 26:3483-92. [PMID: 22593549 DOI: 10.1096/fj.12-208041] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Pharmacological manipulation of opioid receptors alters feeding behavior. However, the individual contributions of each opioid receptor subtype on energy balance remain largely unknown. Herein, we investigated whether genetic disruption of the δ-opioid receptor (DOR) also controls energy homeostasis. Mice lacking DOR and wild-type mice were fed with standard diet and high-energy diet (HED). Mice were analyzed in vivo with the indirect calorimetry system, and tissues were analyzed by real-time PCR and Western blot analysis. DOR-knockout (KO) mice gained less weight (P<0.01) and had lower fat mass (P<0.01) when compared to WT mice fed an HED. Although DOR-KO mice were hyperphagic, they showed higher energy expenditure (P<0.05), which was the result of an increased activation of the thermogenic program in brown adipose tissue. The increased nonshivering thermogenesis involved the stimulation of uncoupling protein 1 (UCP1; P<0.01), peroxisome proliferator-activated receptor γ coactivator (PGC1α; P<0.05), and fibroblast growth factor 21 (FGF21; P<0.01). DOR deficiency also led to an attenuation of triglyceride content in the liver (P<0.05) in response to an HED. These findings reveal a novel role of DOR in the control of thermogenic markers and energy expenditure, and they provide a potential new therapeutic approach for the treatment of obesity.
Collapse
Affiliation(s)
- Traci A Czyzyk
- Obesity Research, Lilly Research Laboratories, Indianapolis, Indiana, USA
| | | | | | | | | | | | | |
Collapse
|
4
|
Zervou S, Wang YF, Laiho A, Gyenesei A, Kytömäki L, Hermann R, Abouna S, Epstein D, Pelengaris S, Khan M. Short-term hyperglycaemia causes non-reversible changes in arterial gene expression in a fully 'switchable' in vivo mouse model of diabetes. Diabetologia 2010; 53:2676-87. [PMID: 20844862 DOI: 10.1007/s00125-010-1887-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2010] [Accepted: 08/02/2010] [Indexed: 12/13/2022]
Abstract
AIMS/HYPOTHESIS Irreversible arterial damage due to early effects of hypo- or hyperglycaemia could account for the limited success of glucose-lowering treatments in preventing cardiovascular disease (CVD) events. We hypothesised that even brief hypo- or hyperglycaemia could adversely affect arterial gene expression and that these changes, moreover, might not be fully reversible. METHODS By controlled activation of a 'switchable' c-Myc transgene in beta cells, adult pIns-c-MycER(TAM) mice were rendered transiently hypo- and then hyperglycaemic, after which they were allowed to recover for up to 3 months. Immediate and sequential changes in aortic global gene expression from normal glycaemia through hypo- and hyperglycaemia to recovery were assessed. RESULTS Gene expression was compared with that of normoglycaemic transgenic and tamoxifen-treated wild-type controls. Overall, expression of 95 genes was significantly affected by moderate hypoglycaemia (glucose down to 2.5 mmol/l), whereas over 769 genes were affected by hyperglycaemia. Genes and pathways activated included several involved in atherogenic processes, such as inflammation and arterial calcification. Although expression of many genes recovered to initial pre-exposure levels when hyperglycaemia was corrected (74.9%), in one in four genes this did not occur. Quantitative reverse transcriptase PCR and immunohistochemistry verified the gene expression patterns of key molecules, as shown by global gene arrays. CONCLUSIONS/INTERPRETATION Short-term exposure to hyperglycaemia can cause deleterious and persistent changes in arterial gene expression in vivo. Brief hypoglycaemia also adversely affects gene expression, although less substantially. Together, these results suggest that early correction of hyperglycaemia and avoidance of hypoglycaemia may both be necessary to avoid excess CVD risk in diabetes.
Collapse
MESH Headings
- Animals
- Arteries/metabolism
- Arteries/pathology
- Diabetes Mellitus, Experimental/complications
- Diabetes Mellitus, Experimental/genetics
- Diabetes Mellitus, Experimental/metabolism
- Diabetes Mellitus, Experimental/pathology
- Disease Models, Animal
- Female
- Gene Expression/drug effects
- Genes, myc/genetics
- Genes, myc/physiology
- Glucose/pharmacology
- Hyperglycemia/etiology
- Hyperglycemia/genetics
- Hyperglycemia/metabolism
- Hyperglycemia/pathology
- Insulin/genetics
- Mice
- Mice, Inbred C57BL
- Mice, Inbred CBA
- Mice, Transgenic
- Recovery of Function/genetics
- Time Factors
Collapse
Affiliation(s)
- S Zervou
- Department of Cardiovascular Medicine, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Vuong C, Van Uum SHM, O'Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev 2010; 31:98-132. [PMID: 19903933 PMCID: PMC2852206 DOI: 10.1210/er.2009-0009] [Citation(s) in RCA: 342] [Impact Index Per Article: 24.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/09/2009] [Accepted: 10/02/2009] [Indexed: 02/07/2023]
Abstract
Opioid abuse has increased in the last decade, primarily as a result of increased access to prescription opioids. Physicians are also increasingly administering opioid analgesics for noncancer chronic pain. Thus, knowledge of the long-term consequences of opioid use/abuse has important implications for fully evaluating the clinical usefulness of opioid medications. Many studies have examined the effect of opioids on the endocrine system; however, a systematic review of the endocrine actions of opioids in both humans and animals has, to our knowledge, not been published since 1984. Thus, we reviewed the literature on the effect of opioids on the endocrine system. We included both acute and chronic effects of opioids, with the majority of the studies done on the acute effects although chronic effects are more physiologically relevant. In humans and laboratory animals, opioids generally increase GH and prolactin and decrease LH, testosterone, estradiol, and oxytocin. In humans, opioids increase TSH, whereas in rodents, TSH is decreased. In both rodents and humans, the reports of effects of opioids on arginine vasopressin and ACTH are conflicting. Opioids act preferentially at different receptor sites leading to stimulatory or inhibitory effects on hormone release. Increasing opioid abuse primarily leads to hypogonadism but may also affect the secretion of other pituitary hormones. The potential consequences of hypogonadism include decreased libido and erectile dysfunction in men, oligomenorrhea or amenorrhea in women, and bone loss or infertility in both sexes. Opioids may increase or decrease food intake, depending on the type of opioid and the duration of action. Additionally, opioids may act through the sympathetic nervous system to cause hyperglycemia and impaired insulin secretion. In this review, recent information regarding endocrine disorders among opioid abusers is presented.
Collapse
Affiliation(s)
- Cassidy Vuong
- Division of Endocrinology, Charles Drew University of Medicine & Sciences, 1731 East 120th Street, Los Angeles, California 90059, USA
| | | | | | | | | |
Collapse
|
6
|
Morgan LM, Flatt PR, Marks V. Nutrient Regulation of the Enteroinsular Axis And Insulin Secretion. Nutr Res Rev 2007; 1:79-97. [DOI: 10.1079/nrr19880008] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
7
|
Delaigle AM, Senou M, Guiot Y, Many MC, Brichard SM. Induction of adiponectin in skeletal muscle of type 2 diabetic mice: In vivo and in vitro studies. Diabetologia 2006; 49:1311-23. [PMID: 16570160 DOI: 10.1007/s00125-006-0210-y] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2005] [Accepted: 01/17/2006] [Indexed: 12/15/2022]
Abstract
AIMS/HYPOTHESIS Adiponectin is an adipokine that exhibits insulin-sensitising, fat-burning and anti-inflammatory properties as well as modulatory effects on oxidative stress. We examined whether adiponectin could be induced in a non-adipose tissue, skeletal muscle, in response to metabolic or oxidative aggression both in vivo (in a murine model of type 2 diabetes) and in vitro. METHODS Obese and diabetic ob/ob mice were used and compared with lean littermates. Some obese mice were treated with the antioxidant probucol for 3 weeks. At the end of the experiment, blood was sampled and tibialis anterior muscles were collected for mRNA measurement and immunohistochemistry. Additional in vitro experiments were performed on C2C12 myotubes cultured for up to 48 h. RESULTS In spite of hypoadiponectinaemia, Adipoq mRNA levels were markedly increased in the skeletal muscle of ob/ob mice and correlated with systemic oxidative stress. Adipoq upregulation was shown in laser-microdissected myocytes of obese mice. Concomitantly, immunoreactivity for adiponectin was enhanced in obese muscle fibres together with lipid infiltration and local markers of oxidative stress. In cultured C2C12 myotubes, a triglyceride mix and reactive oxygen species producers (H2O2 or a lipoperoxidation end-product) upregulated Adipoq expression and adiponectin production. This effect was reversed by an antioxidant. Finally, treatment of obese mice with probucol also attenuated upregulation in muscle. CONCLUSIONS/INTERPRETATION The paradoxical upregulation of adiponectin in muscle of obese and diabetic mice may result from lipotoxicity and related oxidative stress. This unexpected finding could be viewed as a local protection to counteract ectopic fat deposition and oxidative damage.
Collapse
Affiliation(s)
- A M Delaigle
- Endocrinology and Metabolism Unit, Faculty of Medicine, University of Louvain, Brussels, Belgium
| | | | | | | | | |
Collapse
|
8
|
Abstract
1. Naloxone, which is often regarded as a pure opioid antagonist, produces effects similar to those produced by morphine. 2. In conscious rabbits implanted with an intracerebroventricular (i.c.v.) cannula, naloxone, whether given intravenously (1 mg/kg) or i.c.v. (1-100 microg), produced a significant rise in blood glucose levels. 3. Hyperglycaemia in response to naloxone (1 mg/kg, i.v., or 100 microg, i.c.v.) was not influenced by the selective alpha1-adrenoceptor antagonist WB-4101 given either i.v. (50 microg) or i.c.v. (5 microg). 4. Hyperglycaemia in response to naloxone (1 mg/kg, i.v., or 100 microg, i.c.v.) was completely blocked by pretreatment with the alpha2-adrenoceptor antagonist yohimbine (1 mg/kg, i.v., or 100 microg, i.c.v.). However, hyperglycaemia to i.c.v. naloxone (100 microg) was not influenced by i.v. yohimbine (1 mg/kg). 5. Because naloxone behaves like morphine and produces hyperglycaemia in conscious rabbits, the drug may have an appreciable agonist activity and the hyperglycaemic response to naloxone is principally mediated via alpha2- but not alpha1-adrenoceptors.
Collapse
Affiliation(s)
- H A Abouazra
- Department of Pharmacology, Faculty of Medicine, Al-Arab Medical University, Benghazi, Libya.
| | | |
Collapse
|
9
|
Liu IM, Chi TC, Chen YC, Lu FH, Cheng JT. Activation of opioid mu-receptor by loperamide to lower plasma glucose in streptozotocin-induced diabetic rats. Neurosci Lett 1999; 265:183-6. [PMID: 10327161 DOI: 10.1016/s0304-3940(99)00226-8] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
We investigated the effect of loperamide, a selective agonist of opioid mu-receptor, on the plasma glucose in diabetic rats induced by an intravenous injection of streptozotocin (STZ; 60 mg/kg). Intravenous injection of loperamide induced a dose-dependent decrease of plasma glucose in fasting STZ-diabetic rats at 30 min later, but did not modify the plasma glucose level in Wistar rats. Plasma glucose lowering effect of loperamide was abolished by the pretreatment with naloxone or naloxonazine at the dose sufficient to block opioid mu-receptor. In isolated skeletal muscle, loperamide enhanced the glucose uptake into soleus muscles in a concentration-dependent manner. Blockade of this action by naloxonazine indicated the mediation of opioid mu-receptor. These results suggest that an activation of opioid mu-receptor by loperamide can increase the utilization of glucose in peripheral tissue to lower the plasma glucose in STZ-diabetic rats.
Collapse
MESH Headings
- Animals
- Antidiarrheals/pharmacology
- Blood Glucose/drug effects
- Diabetes Mellitus, Experimental/drug therapy
- Diabetes Mellitus, Experimental/metabolism
- Dose-Response Relationship, Drug
- Glucose/pharmacokinetics
- Hyperglycemia/drug therapy
- Hyperglycemia/metabolism
- Injections, Intravenous
- Loperamide/pharmacology
- Male
- Muscle, Skeletal/metabolism
- Naloxone/analogs & derivatives
- Naloxone/pharmacology
- Narcotic Antagonists/pharmacology
- Rats
- Rats, Wistar
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/antagonists & inhibitors
- Receptors, Opioid, mu/metabolism
Collapse
Affiliation(s)
- I M Liu
- Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan City, Taiwan
| | | | | | | | | |
Collapse
|
10
|
Abstract
Autoradiography was used to demonstrate beta-endorphin and delta-opioid receptors in muscles of normal and obese-diabetic mice. The density of the receptors was significantly higher in the obese-diabetic mice. In both normal and diabetic mice, glycolytic and oxidative fibers exhibited the beta-endorphin receptors. However, a significantly greater density of beta-endorphin receptors was observed in the extensor digitorum longus muscles than in the soleus muscles in the diabetic mice. In normal muscles the beta-endorphin receptors were largely restricted to regions where endplates were present, but in the obese-diabetic mice they were densely distributed along the length of the muscle fibers.
Collapse
MESH Headings
- Acetylcholinesterase/analysis
- Animals
- Diabetes Mellitus/metabolism
- Diabetes Mellitus, Type 2/metabolism
- Female
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Obese
- Motor Endplate/metabolism
- Muscle Fibers, Skeletal/metabolism
- Muscle, Skeletal/cytology
- Muscle, Skeletal/metabolism
- Muscle, Skeletal/pathology
- Obesity
- Receptors, Opioid/metabolism
- Receptors, Opioid, delta/metabolism
- Reference Values
Collapse
Affiliation(s)
- A A Evans
- Department of Physiology, Medical School, University of Birmingham, Edgbaston, UK
| | | |
Collapse
|
11
|
Abstract
Autoradiography was used to study the opioid receptors in soleus and extensor digitorum longus (EDL) muscles from normal mice and mice with type II diabetes. Binding sites for [125I]beta-endorphin were present on the surface membranes in muscles from normal mice. The density of receptors was higher in muscles from obese diabetic mice. The specific delta-opioid ligands DPDPE and [D-Ala2]deltorphin-II inhibited the binding of [125I]beta-endorphin whereas mu and kappa agonists did not. Therefore, the opioid receptor present in skeletal muscle fibers of the mouse is of the delta subtype and the number of these receptors is increased in type II diabetes in the mouse.
Collapse
MESH Headings
- Analgesics/pharmacology
- Animals
- Autoradiography
- Binding, Competitive
- Cell Membrane/metabolism
- Diabetes Mellitus/genetics
- Diabetes Mellitus/metabolism
- Diabetes Mellitus, Type 2/metabolism
- Enkephalin, D-Penicillamine (2,5)-
- Enkephalins/pharmacology
- Iodine Radioisotopes
- Mice
- Mice, Obese
- Muscle, Skeletal/metabolism
- Obesity
- Oligopeptides/pharmacology
- Receptors, Opioid, delta/analysis
- Receptors, Opioid, delta/metabolism
- Reference Values
- beta-Endorphin/metabolism
Collapse
Affiliation(s)
- A A Evans
- Department of Physiology, Medical School, University of Birmingham, UK
| | | | | |
Collapse
|
12
|
Bhathena SJ, Berlin E, Judd JT, Law JS, Castro JS, Bhagavan HN, Ballard-Barbash R, Nair PP. Plasma opioid peptides and ACTH responses to fish oil and vitamin E supplementation in male subjects. J Nutr Biochem 1993. [DOI: 10.1016/0955-2863(93)90019-s] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
13
|
Hughes S, Smith ME, Bailey CJ. Beta-endorphin and corticotropin immunoreactivity and specific binding in the neuromuscular system of obese-diabetic mice. Neuroscience 1992; 48:463-8. [PMID: 1318515 DOI: 10.1016/0306-4522(92)90505-v] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Immunoreactivity for two derivatives of pro-opiomelanocortin, beta-endorphin and alpha-melanocortin (or corticotropin), was demonstrated, using a conventional immunoperoxidase method, in some of the intramuscular nerves in muscle sections from obese diabetic (ob/ob) mice and homozygous lean (+/+) mice. The endplate regions were visualized in the sections by staining for acetylcholinesterase reaction product. The proportion of muscle endplates with beta-endorphin-immunoreactive motor nerves was approximately 2.5-fold higher in soleus and extensor digitorum longus muscles and approximately 1.5-fold higher in the diaphragm of the obese (ob/ob) mice compared to the normal lean mice. The proportion of muscle endplates with alpha-melanotropin-immunoreactive motor nerves was between 30 and 53% lower, depending on the muscle type, in the ob/ob mice compared to the lean mice. The muscles of ob/ob and lean mice were investigated for the presence of specific binding sites for [125I]beta-endorphin and for [125I]corticotropin, using autoradiography. Some muscle fibres in soleus, extensor digitorum longus and diaphragm in both the ob/ob and the lean mice exhibited specific binding sites for the radioactive ligands. The binding sites were distributed over the entire surface in these muscle fibres. In the ob/ob mice the number of muscle fibres with specific [125I]beta-endorphin binding sites was six-fold higher in soleus and approximately 10-fold higher in extensor digitorum longus and diaphragm, than in the corresponding muscles of the lean mice. In contrast, the number of muscle fibres with specific [125I]corticotropin binding sites was similar in obese (ob/ob) and lean mice.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- S Hughes
- Department of Physiology, Medical School, University of Birmingham, U.K
| | | | | |
Collapse
|
14
|
Khawaja XZ, Green IC. Studies on the effects of glucose in vitro and of the glycaemic state in vivo on the binding characteristics of mu, delta and kappa opiate receptors in mouse brain. Life Sci 1992; 50:1273-81. [PMID: 1314928 DOI: 10.1016/0024-3205(92)90327-l] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The effect of glucose on the binding characteristics of opiate receptor subtypes was investigated in brain membranes from normoglycaemic lean Aston (C57BL/6J) mice using [3H][D-Ala2,MePhe4,Gly5-ol]enkephalin (DAMGO), [3H][D-Pen2,D-Pen5]enkephalin (DPDPE) and [3H]U69,593 as selective ligands for mu, delta and kappa opiate receptors respectively. The equilibrium dissociation constants (Kd) and maximal binding capacities (Bmax) of [3H]DAMGO and [3H]DPDPE were unaltered by 20mM glucose in vitro. Similarly, [3H]U69,593 binding was not modified by increasing the concentration of glucose from 0 to 20mM (P between 0.10 and 0.05), or by the presence of 20mM fructose and of 20mM 3-O-me-glucose, a non-metabolisable sugar, in the incubation medium. The nonselective opiate ligand, [3H]diprenorphine, bound with similar affinity and binding capacity to brain membranes prepared from control and streptozotocin-diabetic Swiss (CD1) mice. The addition of 20mM glucose or of 20mM fructose in vitro induced no changes in their binding parameters. The affinity and binding capacity of [3H]U69,593 to STZ-diabetic Swiss mouse brain membranes was not significantly different to that of normoglycaemic controls; 20mM glucose in vitro had no effect on ligand binding to kappa sites in STZ-diabetic mouse brain membranes. We conclude that glucose does not interact directly with the opiate receptor to modfy it in such as way as could explain the altered sensitivity to different opioid agonists seen in obese and hyperglycaemic animal models in vivo.
Collapse
MESH Headings
- Animals
- Benzeneacetamides
- Binding, Competitive
- Brain/drug effects
- Brain/metabolism
- Diabetes Mellitus, Experimental/metabolism
- Enkephalin, Ala(2)-MePhe(4)-Gly(5)-
- Enkephalin, D-Penicillamine (2,5)-
- Enkephalins/metabolism
- Glucose/pharmacology
- Ligands
- Mice
- Mice, Inbred C57BL
- Pyrrolidines/metabolism
- Receptors, Opioid/metabolism
- Receptors, Opioid, delta
- Receptors, Opioid, kappa
- Receptors, Opioid, mu
- Streptozocin
Collapse
Affiliation(s)
- X Z Khawaja
- School of Biological Sciences, University of Sussex, U.K
| | | |
Collapse
|
15
|
Khawaja XZ, Chattopadhyay AK, Green IC. Increased beta-endorphin and dynorphin concentrations in discrete hypothalamic regions of genetically obese (ob/ob) mice. Brain Res 1991; 555:164-8. [PMID: 1681994 DOI: 10.1016/0006-8993(91)90874-u] [Citation(s) in RCA: 31] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Disturbances in hypothalamic beta-endorphin and dynorphin levels were investigated in non-fasted genetically obese (ob/ob) and homozygous lean mice at 14-15 weeks of age. Eight brain regions were microdissected from fresh, unfixed brain slices, and opioid peptide concentrations were determined in tissue micropunches by radioimmunoassay. A two-fold and five-fold increase in beta-endorphin levels in ob/ob versus lean mice were found in the ventromedial and dorsomedial hypothalamic nuclei respectively. Dynorphin levels were comparable between ob/ob and lean mice in the anterior, lateral, ventromedial and paraventricular hypothalamic areas, but a 5-fold increase in dynorphin concentrations was detected in the dorsomedial hypothalamic nucleus of the ob/ob mouse. These results demonstrate that increased concentrations of beta-endorphin and dynorphin occur in discrete hypothalamic nuclei, which are known to influence food intake and glucose homeostasis. This could signify an important central defect contributing to hyperphagia and glucoregulatory dysfunction in obese mice.
Collapse
Affiliation(s)
- X Z Khawaja
- School of Biological Sciences, University of Sussex, Brighton, U.K
| | | | | |
Collapse
|
16
|
Abstract
Intraperitoneal administration of beta-endorphin (1 mg/kg) to ob/ob mice doubled fasting plasma insulin concentrations within 30 min, while plasma glucose concentrations were unaltered. In lean mice, beta-endorphin failed to alter plasma insulin or glucose responses. In glucose-loaded ob/ob mice, beta-endorphin (1 mg/kg) reduced insulin levels at 40 min, and delayed glucose disposal. A lower dose of beta-endorphin (0.1 mg/kg) decreased plasma insulin at 90 min, with no effect on plasma glucose disposal. In lean mice, only the higher dose of beta-endorphin suppressed the glucose-stimulated rise in plasma insulin concentrations, without affecting plasma glucose. Beta-endorphin's actions were blocked by naltrexone and could not be mimicked by N-acetyl-beta-endorphin. Beta-endorphin (10(-8)M) enhanced insulin release from isolated ob/ob and lean mouse islets incubated in medium containing 6 mM glucose, but inhibited release when 20 mM glucose was present. These effects were naloxone reversible. The results indicate that 1) ob/ob mice display a greater magnitude of response in vivo to beta-endorphin's actions on insulin release compared with lean mice, 2) high concentrations of beta-endorphin exacerbate glucose disposal in ob/ob mice. 3) the prevailing glucose concentration is an important determinant of whether beta-endorphin's effects on insulin release will be stimulatory or inhibitory and 4) these actions are mediated via opiate receptors.
Collapse
Affiliation(s)
- X Z Khawaja
- School of Biological Sciences, University of Sussex, Brighton, England
| | | |
Collapse
|
17
|
Ahrén B. Effects of beta-endorphin, met-enkephalin, and dynorphin A on basal and stimulated insulin secretion in the mouse. INTERNATIONAL JOURNAL OF PANCREATOLOGY : OFFICIAL JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PANCREATOLOGY 1989; 5:165-78. [PMID: 2574736 DOI: 10.1007/bf02924417] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Since opioid peptides and opiate receptors have been demonstrated in the pancreatic islets, we investigated the effects of beta-endorphin, met-enkephalin, and dynorphin A, on basal and stimulated insulin secretion in the mouse. Each of the three opioid peptides was injected intravenously (0.06-64 nmol/kg) alone or together with each of the three insulin releasing agents glucose (2.8 mmol/kg), carbachol (cholinergic agonist, 0.16 mumol/kg), or terbutaline (beta 2-adrenoceptor agonist, 3.6 mumol/kg). It was found that beta-endorphin, met-enkephalin, and dynorphin A were all without effect on basal plasma insulin levels, except a slight elevation by beta-endorphin induced at 2 min after its injection at 64 nmol/kg (to 41 +/- 2 microU/mL vs 28 +/- 4 microU/mL in controls; p less than 0.05). Glucose- and terbutaline-induced insulin secretion were inhibited by beta-endorphin at the lower dose levels of 0.25 (p less than 0.01) and 1 nmol/kg (p less than 0.05). This effect was counteracted by the opiate receptor antagonist naloxone (500 micrograms/kg). In contrast, beta-endorphin at the high dose levels of 16 and 64 nmol/kg augmented the glucose- and terbutaline-induced insulin secretion (p less than 0.05). Carbachol-induced insulin secretion was not affected by beta-endorphin at the lower dose levels but augmented by the peptide at 64 nmol/kg (p less than 0.01). Met-enkephalin inhibited glucose- (p less than 0.01) and terbutaline- (p less than 0.05) induced insulin secretion at the high dose rates of 16 and 64 nmol/kg, but the peptide was without effect on carbachol-induced insulin secretion. The inhibitory effects were counteracted by naloxone. Dynorphin A did not affect stimulated insulin secretion at any of the dose levels tested. In summary, in the mouse 1. beta-Endorphin at low dose levels inhibits and at high dose levels augments stimulated insulin secretion; 2. Met-enkephalin inhibits stimulated insulin secretion; and 3. Dynorphin A does not affect insulin secretion. It is suggested that the main influence of beta-endorphin and met-enkephalin under in vivo conditions in the mouse is to inhibit stimulated insulin secretion.
Collapse
Affiliation(s)
- B Ahrén
- Department of Pharmacology, Lund University, Sweden
| |
Collapse
|
18
|
Surwit RS, McCubbin JA, Kuhn CM, Cochrane C, Feinglos MN. Differential glycemic effects of morphine in diabetic and normal mice. Metabolism 1989; 38:282-5. [PMID: 2645504 DOI: 10.1016/0026-0495(89)90089-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
C57BL/6J ob/ob mice, C57BL/6J+/? lean mice and A/J mice were given injections of 10 mg/kg of morphine or an equal volume of saline, and then blood was sampled by retroorbital sinus puncture. In addition, animals from each strain were exposed to a brief experimental stress ten minutes after the administration of morphine or saline. While morphine produced significant increases in serum glucose in albino mice, morphine lowered blood insulin in both C57BL/6J ob/ob and C57BL/6J+/? mice. Morphine significantly lowered blood insulin in A/J mice, but effects in C57BL/6J mice were not significant. In contrast, morphine attenuated blood glucose and insulin during stress in C57BL/6J ob/ob but did not significantly affect either glucose or insulin during stress in lean C57BL/6J or A/J mice. These results are interpreted in the light of other data suggesting that endogenous opiates modulate the effects of sympathetic nervous system activity in type II diabetes.
Collapse
Affiliation(s)
- R S Surwit
- Department of Psychiatry, Duke University Medical Center, Durham, NC 27710
| | | | | | | | | |
Collapse
|
19
|
Khawaja XZ, Bailey CJ, Green IC. Central mu, delta, and kappa opioid binding sites, and brain and pituitary beta-endorphin and met-enkephalin in genetically obese (ob/ob) and lean mice. Life Sci 1989; 44:1097-105. [PMID: 2523015 DOI: 10.1016/0024-3205(89)90337-8] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The equilibrium dissociation constants and maximal binding capacities of 3H-dihydromorphine (DHM), 3H-D-Ala2-D-leu3-enkephalin (DADL), and 3H-dynorphin A(1-8) for their respective mu, delta, and kappa opiate binding sites were studied in brain membrane preparations from lean and genetically obese-hyperglycaemic (Aston ob/ob) mice. The concentration of kappa binding sites was 2.7 fold higher in obese compared with lean mouse brain (231 +/- 44.6 versus 83.8 +/- 10.3 fmoles 3H-dynorphin/mg protein respectively, mean +/- SEM). The concentration of delta binding sites in obese was 1.6 fold that in lean mouse brain (94.5 +/- 8.6 versus 59.5 +/- 6.5 fmoles 3H-DADL/mg protein). In contrast, the concentration of brain mu receptors was 40% lower in obese compared with lean mice (20.8 +/- 2.19 and 34.8 +/- 3.1 fmoles 3H-DHM/mg protein respectively). Binding affinities of delta and kappa sites for their respective ligands were not significantly different in lean v. obese mice. However, for mu sites, lean mouse binding data showed two affinities, one was not significantly different from obese (0.35 nM) the second was lower (1.18 nM) for DHM. Increases of approximately 5 fold and 3 fold in the brain content of beta-endorphin and met-enkephalin respectively, and no differences in brain dynorphin levels, were demonstrated in obese mice compared with lean controls. In obese mice, pituitary beta-endorphin content was 9 fold higher, met-enkephalin 4 fold higher and dynorphin 12 fold higher than in lean mice. The striking differences in opioid binding-site characteristics and in endogenous opioid peptide levels in obese compared with lean mice may contribute to the hyperphagia and, directly or indirectly, to the development of hyperglycaemia and hyperinsulinaemia in obese mice.
Collapse
|
20
|
Bray GA, York DA, Fisler JS. Experimental obesity: a homeostatic failure due to defective nutrient stimulation of the sympathetic nervous system. VITAMINS AND HORMONES 1989; 45:1-125. [PMID: 2688303 DOI: 10.1016/s0083-6729(08)60393-3] [Citation(s) in RCA: 142] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The basic hypothesis of this review is that studies on models of experimental obesity can provide insight into the control systems regulating body nutrient stores in humans. In this homeostatic or feedback approach to analysis of the nutrient control system, we have examined the afferent feedback signals, the central controller, and the efferent control elements regulating the controlled system of nutrient intake, storage, and oxidation. The mechanisms involved in the beginning and ending of single meals must clearly be related to the long-term changes in fat stores, although this relationship is far from clear. Changes in total nutrient storage in adipose tissue can arise as a consequence of changes in the quantity of nutrients ingested in one form or another or a decrease in the utilization of the ingested nutrients. A change in energy intake can be effected by increased size of individual meals, increased number of meals in a 24-hour period, or a combination of these events. Similarly, a decrease in utilization of these nutrients can develop through changes in resting metabolic energy expenditure which are associated with one of more of the biological cycles such as protein metabolism, triglyceride for glycogen synthesis and breakdown, or maintenance of ionic gradients for Na+ + K+ across cell walls. In addition, differences in energy expenditure related to the thermogenesis of eating or to the level of physical activity may account for differences in nutrient utilization.
Collapse
|
21
|
Bailey CJ, Flatt PR. Glucoregulatory effects of bombesin in lean and genetically obese hyperglycaemic (ob/ob) mice. COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY. B, COMPARATIVE BIOCHEMISTRY 1987; 88:359-62. [PMID: 3315420 DOI: 10.1016/0305-0491(87)90127-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
1. Plasma glucose and insulin responses to bombesin were examined in 12-15-week-old 12 hr fasted lean and genetically obese hyperglycaemic (ob/ob) mice. 2. Bombesin (1 mg/kg ip) produced a prompt but transient increase of plasma insulin in lean mice (maximum increase of 50% at 5 min), and a more slowly generated but protracted insulin response in ob/ob mice (maximum increase of 80% at 30 min). Plasma glucose concentrations of both groups of mice were increased by bombesin (maximum increases of 40 and 48% respectively in lean and ob/ob mice at 15 min). 3. When administered with glucose (2 g/kg ip), bombesin (1 mg/kg ip) rapidly increased insulin concentrations of lean and ob/ob mice (maximum increases of 39 and 63% respectively at 5 min). Bombesin did not significantly alter the rise of plasma glucose after exogenous glucose administration to these mice. 4. The results indicate that bombesin exerts an insulin-releasing effect in lean and ob/ob mice. The greater insulin-releasing effect in ob/ob mice renders bombesin a possible component of the overactive entero-insular axis in the ob/ob mutant, especially if it acts within the islets as a neurotransmitter or paracrine agent.
Collapse
Affiliation(s)
- C J Bailey
- Department of Molecular Sciences, Aston University, Birmingham, UK
| | | |
Collapse
|